Overview
Medical device companies of all sizes turn to Epstein Becker Green to represent them in a wide variety of health law matters, including Medicare and FDA-related issues.
Within our Health Care and Life Sciences practice, we have a special focus on the medical device industry. We are thought leaders in medical device regulation, and our attorneys have been involved in most of the important regulatory and payment issues affecting the device industry.
From a technology standpoint, our clients include many of the largest manufacturers of:
- In vitro diagnostic products
- Hospital beds
- Durable medical equipment
- Orthopedic implants
- Cardiovascular products
- Drug delivery products
- Other combination products
Epstein Becker Green attorneys also have an in-depth focus on the regulation of mobile health, telemedicine, health information technology, and other software used in the health care context. In that regard, we represent a number of manufacturers of wireless health technologies as well as the mHealth Regulatory Coalition and the CDS Coalition. Through these representations, we have been integrally involved in the development of global regulatory policy for mHealth and clinical decision support software.
Our attorneys have written textbooks and numerous chapters explaining medical device law and regulation, testified before Congress on these issues, and taught at top U.S. law schools. Moreover, one of our attorneys, in the mid-1990s, spearheaded the effort to convince the FDA to adopt Good Guidance Practices.
Services/Scope of Practice
Epstein Becker Green provides complete legal support for medical device manufacturers on all regulatory and payment matters. Our services include:
- Helping clients manage FDA inspections, improve quality systems, and design practical and effective compliance systems
- Developing, drafting, and implementing market introduction strategies for complex technologies that don't fit neatly into existing pathways
- Establishing strategic marketing claims for maximum reimbursement, with a special focus on the evidence requirements for FDA clearance, and helping clients navigate the coding, coverage, and payment system
- Developing an appropriate set of Good Promotional Practices (GPPs) that are specific to the manufacturer and guide its marketing campaigns in effective directions
- Providing counsel on privacy and security matters to manufacturers not covered by HIPAA that may contract with, or provide equipment and services to, covered entities and business associates, and devising strategies for anticipating customer demands and for common law and consumer privacy compliance
- Providing counsel regarding risk management during clinical trials, and drafting policies, GPPs, appropriate contractual agreements, and informed consent forms that align with company policies and procedures
- Representing clients during noncompliance matters
- Analyzing the impact on current and pending legislation and regulations that address FDA issues
- Defending medical device manufacturers in litigation involving federal and state agencies, as well as qui tam or "whistleblower" actions started by individuals acting in the name of the government and seeking a share of any recoveries, and helping clients with investigations
- Structuring, negotiating, documenting, and implementing complex health care transactions (such as mergers and acquisitions), for medical device manufacturers, including conducting health regulatory due diligence, addressing potential health regulatory exposures, and overseeing compliance audits
- Guiding companies in the drug, device, and biologics industries, including members of the Combination Product Coalition, on actively communicating the industries' concerns and desires with respect to new combination product policies at FDA
Epstein Becker Green also assists medical device manufacturers with a wide range of services related to federal and state transparency reporting, including:
- Counseling on legal requirements and the interpretation of relevant laws and regulations
- Conducting assessments designed to identify gaps in federal and state transparency reporting compliance
- Implementing action plans to correct deficiencies in the implementation of federal and state transparency reporting compliance
- Devising strategy for addressing infrastructure and resource matters
- Advising on the implementation of aggregate spend reporting systems and coordination with third-party vendors
- Drafting policies, procedures, and working instructions to capture the implementation of state and federal law requirements
- Training sales forces, home office personnel, and other relevant employees and vendors regarding federal and state transparency reporting requirements
- Training health care professionals regarding federal and/or state transparency reporting requirements
- Preparing transmittal letters and other communications with relevant government agencies
- Drafting comments to proposed regulations
- Responding to inquiries from government authorities and other third-party inquiries
- Analyzing preemption matters
- Informing clients of federal and state law developments
Read less
Focus Areas
Experience
- Led the effort, due to our long involvement with in vitro diagnostic clients, to move the administration of CLIA from the Centers for Disease Control and Prevention to the FDA and to improve the operation of the waiver petition process.
- Reviewed the promotional practices of one of the world's largest medical device manufacturers, then worked with executive management to create a set of GPPs to ensure compliance with FDA and fraud and abuse requirements.
- Helped a client respond to multisite FDA inspections that resulted in multiple Form FDA-483s, Untitled Letters, and Warning Letters; then assisted the same client with structuring and executing a company-wide remediation to improve compliance with FDA requirements.
- Conducted a due diligence review of a medical device manufacturer that uncovered significant FDA compliance issues previously unknown to the potential investors.
- Drafted and negotiated clinical trial agreements for a pivotal Phase III study, then transitioned the company to a treatment protocol and cost recovery program while FDA marketing applications were being compiled, submitted, and reviewed by the FDA.
- Helped a tissue product manufacturer interpret the nuances of marketing and promotional issues for tissue products and medical devices, and applied those nuanced requirements to their website and other marketing practices.
- Trained a major medical device manufacturer on Good Clinical Practices and other clinical trial issues, then assisted the manufacturer in enhancing its clinical research SOPs to reflect current requirements and best practices.
- Created for a major electronics manufacturer an extensive regulatory and reimbursement strategy for telehealth products, and advised management on the potential risks and benefits to various pathways.
- Helped a multibillion-dollar drug and combination product manufacturer execute a recall on a major product line.
Contacts
- Member of the Firm
- Board of Directors / Member of the Firm
- Member of the Firm
Media
Events
Upcoming Events
- December 10-11, 2024
Past Events
- February 5–7, 2024
Insights
Insights
- Media CoverageLisa Pierce Reisz Quoted in “New Health Apps May Pose Challenges to Patient Privacy”3 minute read
- Media CoverageMarylana Saadeh Helou Quoted in “FDA Offers Road Map for Remote Trials, but Questions Linger”2 minute read
- BlogsUnpacking Averages: Assessing FDA’s Postmarket Surveillance Under Section 52211 minute read
- Media CoverageBradley Merrill Thompson Quoted in “Convergence: Experts Offer Advice on Leveraging AI in Regulatory”3 minute read
- Media CoverageBBA Spotlight Series: Get to Know Emerging Leaders in Boston Law–Marylana Saadeh Helou8 minute read
- BlogsUnpacking Averages: How Old Are Medical Devices on the US Market?5 minute read
- Media CoverageDavid Shillcutt Quoted in “Proposed Digital Therapy Codes Good Idea with Barriers: Experts”2 minute read
- Media CoverageJames Boiani Quoted in “CMS Takes Baby Steps in New 'Breakthrough' Device Policy”2 minute read
- BlogsPodcast: The DEA Is Knocking at Your Door . . . Are You Prepared? – Diagnosing Health Care2 minute read
- BlogsPodcast: The Future of Laboratory Testing Just Got a Little Clearer - FDA's Final Rule on LDTs – Diagnosing Health Care2 minute read
- PublicationsFDA Issues Long-Anticipated Draft Guidance on Diversity Action Plans16 minute read
- BlogsUnpacking Averages: Intended Use Words Most Common to Devices That Require Clinical Trials8 minute read
- Firm Announcements
Elizabeth Scarola Named to the 2024 Florida Rising Stars List
7 minute read - Media CoverageBradley Merrill Thompson Cited in “AI Regulation: Global Picture Balances Innovation and Insight”3 minute read
- Media CoverageBradley Merrill Thompson Quoted in “Experts Advise Against Prescriptive FDA Policies for Regulating AI”3 minute read
- BlogsIt’s Been a Long Time Coming – FDA’s Final Rule on Regulation of Laboratory Developed Tests (LDTs) as Medical Devices ...8 minute read
- Media Coverage
Kate Heffernan Featured in AHLA’s Speaking of Health Law Podcast, “Trends Related to Research Misconduct” ...
1 minute read - Media CoverageCSHA Members Join Epstein Becker Green1 minute read
- Media CoverageRaja Sékaran, John Puente, Melissa Borrelli Featured in “Wake Up Call: Laterals, Moves, In-House”1 minute read
- Media CoverageEpstein Becker Green Grows Health Care & Life Sciences Practice2 minute read
- Media CoverageEpstein Becker Green Adds 6-Atty Healthcare Team in San Francisco2 minute read
- Media Coverage
Epstein Becker Green’s Bay Area Healthcare Attorney Additions Featured in the San Francisco Business Times
1 minute read - Firm AnnouncementsEpstein Becker Green Fuels West Coast Momentum with Six-Attorney Health Care Team6 minute read
- BlogsUnpacking Averages: Adverse Events for Device-Lead Combination Products7 minute read
- Media CoverageWes Scott Featured in "In Charge 2024: Finance"1 minute read
- PublicationsFDA and OHRP Issue Joint Draft Guidance on Content, Organization, and Presentation of Consent Forms for Research ...9 minute read
- BlogsMaking Moves – FDA’s LDT Proposed Rule Sent to OMB for Review2 minute read
- PublicationsHealth Care M&A Insights: Q4 2023 & Outlook for 2024 Deal Activity4 minute read
- Media CoverageMegan Robertson Quoted in “FDA and CMS Leaders Unite Over Proposed Lab Test Rule”2 minute read
- Media CoverageAlaap Shah Quoted in “Don’t Worry, You (Probably) Won’t Have to Deal with ONC: Algorithm Transparency Rule May Have ...2 minute read
- Media CoverageWes Scott Featured in “People on the Move”1 minute read
- Media CoverageWes Scott Featured in “Legal Notes: New Partners”2 minute read
- Media CoverageBradley Merrill Thompson Discusses Clinical Decision Support, Medical Devices, and AI in Yale Video1 minute read
- Firm AnnouncementsEpstein Becker Green Expands Capabilities in Nashville with M&A Attorney Wes Scott3 minute read
- Media CoverageWes Scott Featured in “Epstein Becker Adds M&A Specialist to Health Care Practice in Nashville”4 minute read
- BlogsUnpacking Averages: Analyzing FDA Device-Related Citizens Petitions by Topic10 minute read
- BlogsSharing Scientific Information with HCPs on Unapproved Uses of Medical Products: Dos and Don’ts Under FDA’s New Draft ...14 minute read
- Media CoverageBradley Merrill Thompson Quoted in “The Problem with FDA's Warning to Abiomed”5 minute read
- PublicationsNavigating the Medtech GenAI Journey: A Policy Primer2 minute read
- PublicationsORI Releases Notice of Proposed Rulemaking to Update 2005 Public Health Service Policies on Research Misconduct ...7 minute read
- BlogsUnpacking Averages: FDA’s Extraordinary Delay in Resolving Citizen Petitions17 minute read
- Media CoverageJames Boiani Quoted in “Proposed FDA Rule Sets Stage for New Round of Battle Over LDT Regulation”5 minute read
- BlogsFull Steam Ahead: FDA Releases Proposed LDT Rule in Advance of Looming Government Shutdown4 minute read
- Media CoverageJames Boiani Quoted in “FDA Wants Oversight of Lab-Developed Tests”2 minute read
- PublicationsA Topic-Based Analysis of FDA Responses to FOIA Requests1 minute read
- Media CoverageJames Boiani Quoted in “NY State Database Offers Glimpse into Laboratory-Developed Testing Landscape”3 minute read
- Media CoverageJames Boiani Quoted in “FDA Moves to Modernize Medical Devices Premarket Program”3 minute read
- PublicationsState Regulation of Pharmacy Benefit Managers: Tenth Circuit Holds That ERISA and Medicare Part D Preempt Key Parts of ...25 minute read
- Media CoverageEpstein Becker Green Update Cited in “Physicians Could Be in Financial Danger with This Stark Law Change”2 minute read
- Media CoverageBonnie Odom Quoted in “Health Care’s AI Embrace Boosts Workforce Despite Privacy Risks”2 minute read